Acta Med. 2012, 55: 180-185
https://doi.org/10.14712/18059694.2015.43
Therapeutic Erythrocytapheresis in the Initial Treatment of Hereditary Hemochromatosis
References
1. PC, Barton JC. How I treat hemochromatosis. Blood 2010; 22; 116(3): 317–25.
<https://doi.org/10.1182/blood-2010-01-261875>
2. BR, Adams PC, Kowdley KV, Powell LW, Tavill AS. Diagnosis and Management of Hemochromatosis: 2011 Practice Guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54(1): 328–343.
<https://doi.org/10.1002/hep.24330>
<PubMed>
3. CD, Conry-Cantilena C, Mason G, et al. MCV as a guide to phlebotomy therapy for hemochromatosis. Transfusion 2001; 41(6): 819–27.
<https://doi.org/10.1046/j.1537-2995.2001.41060819.x>
4. P, Ball S, Rofail D, Cannon H, Jin VW. Hereditary hemochromatosis: patient experiences of the disease and phlebotomy treatment. Transfusion. 2011; 51(6): 1331–8.
<https://doi.org/10.1111/j.1537-2995.2010.02997.x>
5. G, Kulaksiz H. Diagnosis and treatment in hereditary hemochromatosis. Deutsche Med Wochenschr 2009; 134(50): 2565–72.
<https://doi.org/10.1055/s-0029-1243062>
6. EK, Powell LW, Olynyk JK. Natural history and management of HFE-hemochromatosis. Semin Liver Dis 2011; 31(3): 293–301.
<https://doi.org/10.1055/s-0031-1286060>
7. BL, Tucker DC, Barton JC. Patient compliance with phlebotomy therapy for iron overload associated with hemochromatosis. Am J Gastroenterol 2003; 98(9): 2072–7.
<https://doi.org/10.1111/j.1572-0241.2003.07292.x>
8. JR. Risks in blood-letting in therapy of hemochromatosis. Gastroenterologia 1957; 87(3–4): 186–91.
<https://doi.org/10.1159/000200840>
9. Horák J. a kol. Hemochromatóza. Praha: Grada Publishing, 2010: 232.
10. J. Czech Hepatologic Society of the Czech Medical Society. The standard diagnostic and therapeutic method in genetic (hereditary) hemochromatosis. The recommended method of the Czech Hepatologic Society of the Czech Medical Society of J. E. Purkyne. Vnitr Lek 2006; 52(2): 173–5.
11. P, Codaccioni JL, Fabre M, Marquier A. Fatal complication after 2 bleedings during the treatment of hemochromatosis. Diabete 1967; 15(1): 70–2. French.
12. M, Vališ M, Bláha M, Strnadová B, Malý J. Therapeutic Plasmapheresis in neurology – our experience. Aktuality z Nefrologie 2010; 16(2): 44–50.
13. M, Roerdinkholder-Stoelwinder B, Rombout-Sestrienkova E, de Grip WJ, Bos HJ, Bosman GJ. Red cell concentrates of hemochromatosis patients comply with the storage guidelines for transfusion purposes. Transfusion 2008; 48(3): 436–41.
<https://doi.org/10.1111/j.1537-2995.2007.01547.x>
14. R, Pelucchi S, Perseghin P, Corengia C, Piperno A. Erythrocytapheresis plus erythropoietin: an alternative therapy for selected patients with hemochromatosis and severe organ damage. Haematologica 2005; 90(5): 717–8.
15. R, Adams PC, Bicheler V. Brissot P, Deugnier Y. Clinical features of genetic haemochromatosis in women compared to men. Ann Intern Med 1997; 127: 105–10.
<https://doi.org/10.7326/0003-4819-127-2-199707150-00002>
16. J, Vaquer P, Galmes A, Obrador A et al. In hereditary hemochromatosis, red cell apheresis removes excess iron twice as fast as manual whole blood phlebotomy. J Clin Apheresis 2002; 17(2): 88–92.
<https://doi.org/10.1002/jca.10024>
17. C. Hereditary hemochromatosis. Med Klin (Munich) 2009; 104(12): 931–46.
<https://doi.org/10.1007/s00063-009-1192-6>
18. A. Hereditary hemochromatosis: pathogenesis, diagnosis, and treatment. Gastroenterology 2010; 139(2): 393–408.
<https://doi.org/10.1053/j.gastro.2010.06.013>
19. MA. Multicomponent apheresis blood collection in the United States: Current status and future directions. Transf Apher Sci 2005; 32: 299–304.
<https://doi.org/10.1016/j.transci.2005.03.002>
20. P, Lefèvre PA. Effectiveness of therapeutic erythrocytapheresis to achieve iron depletion in hereditary type 1 hemochromatosis: report of 30 cases. Transfus Clin Biol 2011; 18(5–6): 553–8.
<https://doi.org/10.1016/j.tracli.2011.04.004>
21. E, Nieman FH, Essers BA, van Noord PA, Janssen MC, van Deursen CT, Bos LP, Rombout F, van den Braak R, de Leeuw PW, Koek GH. Erythrocytapheresis versus phlebotomy in the initial treatment of HFE hemochromatosis patients: results from a randomized trial. Transfusion 2012; 52(3): 470–477.
<https://doi.org/10.1111/j.1537-2995.2011.03292.x>
22. E, van Noord PA, van Deursen CT, Sybesma BJ, Nillesen-Meertens AE, Koek GH. Therapeutic erythrocytapheresis versus phlebotomy in the initial treatment of hereditary hemochromatosis – A pilot study. Transfus Apher Sci. 2007 Jun; 36(3): 261–7.
<https://doi.org/10.1016/j.transci.2007.03.005>
23. E, van Noord PA, Reuser E, Heeremans J, van Deursen CT, Janssen M, Koek GH. Therapeutic Erythrocytapheresis (TE) versus phlebotomy (P) in the treatment of hereditary hemochromatosis (HH) patients: preliminary results from an ongoing randomized clinical trial (NCT 00202436). Transf Apher Sci 2009; 40: 135–136.
<https://doi.org/10.1016/j.transci.2009.01.008>
24. AS, Ulvik RJ, Wentzel-Larsen T, Hervig T. Blood donors with hereditary hemochromatosis. Transfusion 2010; 50(8): 1787–93.
<https://doi.org/10.1111/j.1537-2995.2010.02627.x>
25. T, Seidel K, Storch H et al. A prospective mutlicentre study on the safety of long-term intensive plasmapheresis in donors (SIPLA). Vox Sang 2006; 91: 162–73.
<https://doi.org/10.1111/j.1423-0410.2006.00794.x>
26. O, O’Connell E. Hereditary hemochromatosis: patient support and education. Nursing Standard 2009; 24(3): 49–56.
<https://doi.org/10.7748/ns2009.09.24.3.49.c7272>
